Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of Hepatocellular Carcinoma Combined With Portal Vein Thrombus After Hepatic Resection

NCT03914352 is registered in ClinicalTrials.gov with Cancer Hospital of Guangxi Medical University as lead sponsor.

NCT NCT03914352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03914352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of Hepatocellular Carcinoma Combined With Portal Vein Thrombus After Hepatic Resection
Lead sponsor
Cancer Hospital of Guangxi Medical University
Phase
Not applicable
Overall status
Unknown status
Start date
April 1, 2019
Completion date
January 31, 2020
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma